The human p53 protein acts mainly as a stress inducible transcription factor transactivating several genes involved in cell cycle arrest (e.g. p21) or apoptosis (e.g. Bax, PIG3). Roughly half of all human tumours contains p53 missense mutations. Virtually all tumour-derived p53 mutants are unable to activate Bax transcription but some retain the ability to activate p21 transcription. Identi®cation of these mutants may have valuable clinical implications. We have determined the transactivation ability of 77 p53 mutants using reporter yeast strains containing a p53-regulated ADE2 gene whose promoter is regulated by p53 responsive elements derived from the regulatory region of the p21, Bax and PIG3 genes. We also assessed the in¯uence of temperature on transactivation. Our results indicate that a signi®cant proportion of mutants [16/77 (21%) ; 10/64 (16%) considering only tumour-derived mutants] are transcriptionally active, especially with the p21 promoter. Discriminant mutants preferentially aect less conserved (P50.04, Fisher's exact test), more rarely mutated (P50.006, Fisher's exact test) amino acids. Temperature sensitivity is frequently observed, but is more common among discriminant than non-discriminant mutants (P50.003, Fisher's exact test). Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours that surprisingly were indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays in human cells, but showed gain of function in transformation assays. The incidence of transcriptionally active mutations among this group was signi®cantly higher than in the panel of mutants studied previously (P50.001, Fisher's exact test). Since it is not possible to predict the behaviour of a mutant from ®rst principles, we propose that the yeast assay be used to compile a functional p53 database and ®ll the gap between the biophysical, pharmacological and clinical ®elds. Oncogene (2001) 20, 3573 ± 3579.
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The human p53 gene encodes a nuclear protein that exhibits a plethora of biochemical and biological functions (Ko and Prives, 1996; Levine, 1997; Prives and Hall, 1999) . In response to various genotoxic stresses and oncogenic stimuli, p53 is subject to a number of post-translation modi®cations, including phosphorylation and acetylation, which promote DNA binding and transcriptional activation (Giaccia and Kastan, 1998) . Several downstream p53 target genes have been identi®ed. Some of them (e.g. p21, GADD45) play a role in cell cycle control, inducing G1 and G2 arrest in the presence of DNA damage. Others are involved in the induction of apoptosis (e.g. Bax, IGF-BP3, PIG3), or negatively regulate p53 activity and stability (MDM2).
Roughly half of all human tumours contain p53 mutations (Ko and Hall, 1999) . In contrast with other tumour suppressor genes, which are normally inactivated by chain terminating mutations, p53 is commonly subject to missense mutations, suggesting either that p53 is exceptionally easy to inactivate by amino acid substitutions or that there is a selection for expression of mutant protein.
The latter possibility could re¯ect either a dominant negative eect of mutants over wild type in the heterozygous state or a gain of novel functional properties conferring a selective growth advantage (i.e., gain of function). p53 mutants generally lack DNA binding and transactivation capabilities. However, some mutants retain the ability to transactivate a subset of p53 target genes (Crook et al., 1994) . Typically, these mutants are able to induce p21 waf1 -mediated G1 arrest, but not Bax-mediated apoptosis Rowan et al., 1996) . The likely basis for this dierence is that these mutants have a modestly reduced anity for DNA, allowing them to bind to promoters with high anity p53 binding sites, as in the p21 promoter, but not to promoters with low anity sites, as in the Bax promoter. Using simple yeast functional assays, the same mutants have been shown to be competent for transactivation of p21 but not Bax p53 responsive elements in yeast (Flaman et al., 1998) . Thus, the yeast assay can be used to predict the transcriptional behaviour of a mutant in higher eukaryotes.
Proper classi®cation of p53 mutants may have valuable clinical implications because p21 has been shown to protect against cell killing by chemotherapeutic drugs in some settings (Waldman et al., 1997) . Ultimately, any classi®cation of p53 mutants into predictive categories must be tested directly in prospective clinical trials. To facilitate this process, it is essential to create a coherent, logically based classi®cation of mutants. Key issues to be addressed include: (i) which p53 mutants show selective defects in transactivation of target genes (de®ned as discriminant mutants), (ii) how frequent is this phenomenon, and (iii) can we predict the behaviour of previously uncharacterized mutants? To answer these questions, we examined 77 mutants (Campomenosi et al., 1997; Inga et al., 1997 Inga et al., , 1998 Inga et al., , 1999 Kelly et al., 1999; Monti et al., 2000) that were originally isolated in the yIG397 yeast strain (Flaman et al., 1995) , which expresses an ADE2 reporter gene from a p53-responsive promoter containing three copies of the RGC sequence (Kern et al., 1991) . The YPH-p21, YPH-bax and YPH-PIG3 reporter strains express ADE2 from promoters containing the following p53 responsive elements: p21, 5'-GAACATGTCCCAACATGTTG-3'; bax, 5'-TCACA-AGTTAGAGACAAGCCTGGGCGTGGGCTATAT-TG-3'; PIG3, 5'-CAGCTTGCCCACCCATGCTC-3' (Flaman et al., 1998; Robert et al., 2000) .
Discriminant mutants
Sixteen mutants (21%, 16/77) scored as wild type in YPH-p21; 14 of these have a missense mutation that lies within the core p53 DNA binding domain (Table  1) . Four mutants showed weak activity in the YPH-bax or YPH-PIG3 strains in addition to the wild type activity in YPH-p21 (Table 1) . Five mutants active in YPH-p21 hit mutation hotspots in tumours, but only one is a strong mutation hotspot (282Q). Six of the mutations have never been seen in the IARC database of >14 000 mutations in tumours and cell lines (Hernandez-Boussard et al., 1999) , including two mutations aecting S99, an amino acid located outside the core DNA binding domain. All of the mutants active in YPH-p21 had changes aecting amino acids relatively well conserved during evolution (Table 1 ; Soussi and May, 1996) . Thus, despite aecting conserved residues, discriminant mutations are relatively uncommon in tumours.
Non-discriminant mutants
Sixty-one mutants (61/77, 79%) were transcriptionally inactive in all three reporter strains ( Table 2) . Fifty of them (82%, 50/61) had single missense mutations in the core DNA binding domain. Most of these aected highly conserved amino acids (47/50, 94%) which were also mutation hotspots in tumours (42/50, 82%). The degree of evolutionary conservation was signi®cantly higher than that seen with the core domain mutants Localization of the mutation according to the topological diagram of the core domain (Cho et al., 1994) . Percentage of species in which the speci®c codon is identical to that observed in the human cDNA (data from Soussi and May, 1996) . c Codon recognized as hotspot for mutation; for data and de®nition of the dierent hotspot levels and their statistical signi®cance see Walker et al. (1999). d Mutant expressed in the indicated strain generated white (+), pink (+) or red (7) Four fully inactive mutants had missense mutations located outside the p53 core domain. Only one of these mutations has been seen in tumours (354E). Amino acid 354 is neither a hotspot nor well conserved, although rare changes in this region have previously been shown to aect transcription activation in yeast (Ishioka et al., 1995) . A priori, mutations outside the DNA binding domain would not be expected to produce the subtle changes in alignment of DNA contact residues that determine promoter selectivity, although it is noteworthy that phosphorylation of S315, which is close to two of the mutations in question, can aect DNA binding speci®city in vitro (Wang and Prives, 1995) .
Six nonsense mutations that truncate the protein before the oligomerization domain were also tested (stop codons at amino acid 146, 201, 238, 306, 327, and 331) . As expected for a protein that normally binds DNA as a tetramer, they were mutant in every strain.
The results presented showed that over 20% (16/77) of p53 mutants analysed retain the ability to activate transcription in yeast from a promoter containing the p53 binding site in the p21 promoter. If the analysis is restricted only to mutants found in tumours, the number is still over 15% (10/64). Most of these mutants are inactive on Bax and PIG3 promoter reporters. This probably re¯ects the lower anity even of wild type p53 for the Bax than the p21 site (Friedlander et al., 1996) . The p53 binding site in the PIG3 promoter is also a low anity site (Polyak et al., 1997; Roberts et al., 2000) . Extrapolation to mammalian cells suggests that discriminant mutants should be competent for induction of cell cycle arrest while being defective in induction of Bax and PIG3-mediated Percentage of species in which the speci®c codon is identical to that observed in the human cDNA (data from Soussi and May, 1996) . c Codon recognized as hotspot for mutation; for data and de®nition of the dierent hotspot levels and their statistical signi®cance see Walker et al. (1999). d Amino acid substitution never found in human tumours or cell lines (IARC database http://www.iarc.fr/p53/homepage.htm). NA: not applicable Oncogene p53 mutants discriminate between responsive elements P Campomenosi et al apoptosis, an hypothesis already veri®ed on a restricted number of mutants Rowan et al., 1996) . Many results reported in the literature suggest, however, that Bax and PIG3 are at best minor players and that other target genes make important contributions to p53 dependent apoptosis (Saller et al., 1999) . New potential mediators of p53-dependent apoptosis continue to be identi®ed on a regular basis (Vogelstein et al., 2000) .
Temperature sensitivity
In order to assess the in¯uence of temperature on p53 mutants' ability to transactivate from dierent promoters, every mutant clone in the three strains was incubated at 248C, 308C and 378C (Table 3) . Among the 77 mutants tested, 28 (36%) showed a phenotype in¯uenced by temperature (Table 3) . Most were classical heat sensitive (ts) mutants (20/28, 71%) but some showed a cold sensitive (cs) phenotype (8/28, 29%). A typical result is shown in Figure 1 . The 170R mutant was fully active on the p21 site, cs on Bax, and fully inactive at all three temperatures on PIG3. The 228V mutant was fully active on the p21 site and cs on the other sites, so it should have near normal activity in tumours. Temperature sensitivity (ts or cs) was more common among discriminant than non-discriminant mutants (12/16, 75% vs 16/61, 26%; P50.003, Fisher's exact test). Although the majority of non-discriminant mutants were ts, the 181H and 181G mutants were cs. Since tumours grow at 378C, these mutants probably belong to the discriminant class. Indeed 181H tested at 358C was reported to be discriminant (Flaman et al., 1998) .
To rule out changes in protein stability as a cause for the dierences in activity at dierent temperatures or in dierent strains, p53 protein levels were analysed by Western blotting. This showed that the protein level of the mutants was similar at all temperatures and in every strain (data not shown). We conclude that dierences in phenotype were not due to dierences in protein level.
BRCA-associated p53 mutants
A novel class of p53 mutants found in BRCAassociated tumours has been described (Smith et al., 1999) . Some of them are indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays but show gain of function in transformation assays. Given the importance of p53-dependent transcription activation in all current models for p53 function, the mutants were tested in yeast to determine whether subtle transcriptional defects could be detected (Table 4) . Three mutants (163N, 168Y, 248W) were transcriptionally inactive in all strains at every temperature tested. The incidence of fully inactive mutants is signi®cantly lower than that seen in the randomly selected mutant panel of Tables 1 and  2 (3/12, 25% vs 61/77, 79%; P50.001, Fisher's exact test). In fact the remaining BRCA-associated p53 mutants showed some activity in at least one yeast strain. Consistent with the results obtained in mammalian cells (Smith et al., 1999) four mutants (150I, 199R, 202S, 215C) showed transcriptional activity in yeast indistinguishable from wild type in the p21, Bax and PIG3 reporter strains. The 199R, 202S and 215C mutants do give pink colonies at 358C in a highly sensitive reporter strain containing a single RGC site (yIG468), but the physiological relevance, if any, of such a weak phenotype is unclear (R Iggo, 2001, unpublished data) .
Compared with mammalian assays, the yeast p53 assay is simpler, more consistent and more robust. Indeed, the fact that so many doubtful mutants have in the past been shown unequivocally to have a transcriptional defect in yeast is one of the main arguments for concluding that the key biological target of p53 mutation in tumours is transcription activation. The results with BRCA-associated mutations in yeast force a reassessment of this dogma. In general, the mutants isolated in BRCA-associated tumours appear to be more similar to the discriminant than to the nondiscriminant class of mutants. Remarkably, but consistent with the results obtained in cultured mammalian cells, one third of the BRCA-associated mutants tested showed wild type transcriptional activity in yeast. These results do not necessarily challenge the fundamental assumption that transcription activation is central to p53's tumour suppressor function. For example, the BRCA-associated mutations could interfere with receipt of DNA damage signals (or signals from oncogenic stimuli) by speci®-cally destroying protein ± protein interaction sites in p53. Such interactions might be super¯uous in yeast and detectable in mammalian cells only using complex biological assays. Be that as it may, the clear conclusion is that the yeast p53 mutation screening assay will miss a certain number of p53 mutations in familial breast cancer. This, however, is unlikely to be a problem except in rare familial cases, and the consequent loss of sensitivity must be set against the other advantages of the assay for detection of mutations in clinical material (Flaman et al., 1995 (Flaman et al., , 1998 Waridel et al., 1997; Chappuis et al., 1999; Robert et al., 2000; Duddy et al., 2000) . The existence of partially active p53 mutants, the postulated role of transcription-independent p53 functions in promoting tumour growth, and the development of drugs which can stabilize mutant p53 core domains all suggest that there may be situations where knowing the precise mutation in p53 may have clinical value. Several systems have been developed to classify p53 mutants. In the simplest, mutations in selected domains in the primary structure are assumed to confer a worse prognosis or response to treatment. Despite disagreements about the exact de®nition of the critical residues, a consensus is emerging that the key regions are L2/H1 (aa 163 ± 195) and L3 (aa 236 ± 251) (Borresen et al., 1995; Aas et al., 1996) . It is inferred that breast cancer patients with mutations in these regions fail to respond to anthracyclines (Borresen et al., 1995; Aas et al., 1996) . The L2/H1 and L3`high risk' regions broadly encompass the Zn-binding region of the protein, and mutations are assumed to destroy the protein tertiary structure. The problem with de®nitions of this sort is that many mutations in the chosen region are without eect experimentally (Ory et al., 1994) . A more rigorous de®nition of functional classes of mutant was attempted by Bullock et al. (2000) , based on biophysical principles. Essentially, Bullock et al. (2000) divide p53 mutants according to whether they destabilize the overall structure by more than 3 kcal/mol, and whether a suitably stabilized structure is capable of binding DNA. Mutation of DNA contact residues, for example, can produce a form of protein that is correctly folded but entirely unable to bind DNA. In contrast, mutation of the beta sheets destroys the overall structure at 378C, but is fully compatible with DNA binding at reduced temperatures. Mutations in the Zn-binding region produce the worst of all possible outcomes, a protein that can neither readily fold nor bind DNA when stabilized. This approach has much to commend it, but it is limited to studies on the puri®ed p53 core domain. It can neither explain the phenotype of mutants like 123A in vivo (Freeman et al., 1994) , nor can it be used to predict the behaviour of previously untested mutants. It is also noteworthy that the L2/H1/L3 high risk domains include residues that fall into all but one of the biophysical classes (Bullock et al., 2000) . Since it is not possible to predict the behaviour of a mutant from ®rst principles, we propose that the yeast assay be used to close the gap between the biophysical, pharmacological and clinical ®elds.
The mode of action of the drugs which activate mutant p53 is based on bridging two regions in the beta sheet to stabilize the structure (Foster et al., 1999) . These drugs should be most eective on tumours with 24¡C 30°C 37¡C Figure 1 Example of the results of the analysis of the mutant temperature sensitivity. In order to analyse whether a mutant was able to transactivate the reporter gene under the control of dierent p53 responsive elements, S.cerevisiae haploid strains [YPH-p21: (p21::pCYC1::ADE2) (Flaman et al., 1998) ; YPH-bax (bax::pCYC1::ADE2) (Flaman et al., 1998) ; (YPH-PIG3) (PIG3::pCYC1::ADE2), (Robert et al., 2000) ] were transformed by the LiAc method with pLS76 yeast expression vector (CEN6/ ARS4, LEU2) coding for the human wild type (WT) or mutated (170R) p53 cDNA under an ADH1 constitutive promoter. Transformants were selected on synthetic minimal medium (Difco, Milano, Italy) lacking leucine, but containing a limiting amount of adenine (5 mg/l). The expression of wild type p53 conferred adenine prototrophy (white, normal size colonies), while the expression of a mutant p53 unable to transactivate the ADE2 gene conferred adenine auxotrophy (small red colonies). Transformants (170R mutant and wild type p53) in dierent strains were streaked on appropriate plates and incubated for 3 days at the indicated temperature (248C, left; 308C centre; 378C right) (see scheme above). For each mutant, at least three dierent clones were analysed and the results were reproducible p53 mutations that destabilize the protein but fold correctly at low temperatures. These mutants should normally be temperature sensitive in yeast, but may include other mutants with demonstrable residual activity (i.e. discriminant mutants). Our studies in yeast suggest that one third of mutants (28/77) fall into this category. It would be interesting to determine whether the biophysical approach looking at isolated core domains in vitro or the functional approach testing full length p53 in vivo in yeast will provide a better correlation with clinical response. It is already obvious that rational selection of patients for p53 stabilizing drug therapy will pose a major clinical challenge, and that sequencing alone will only provide guidance when the properties of the mutants are known. The properties of discriminant mutants ± moderate evolutionary conservation and a propensity not to aect tumour hotspots ± mean that pre-existing data will frequently not be available, because the number of such mutants is vast. The p53 yeast assay provides the only practical means to test p53 mutants from individual patients for functional activity, and we propose that it should be included in any future studies of p53 stabilizing drug therapy. 
